首页 | 本学科首页   官方微博 | 高级检索  
     

同步放化疗治疗45例中晚期宫颈癌的临床疗效分析
引用本文:刘晓青,董柱清. 同步放化疗治疗45例中晚期宫颈癌的临床疗效分析[J]. 中国医药科学, 2011, 0(23): 57-58,60
作者姓名:刘晓青  董柱清
作者单位:福建医科大学附属闽东医院放疗科
摘    要:目的探讨同步放化疗治疗中晚期宫颈癌的临床疗效和不良反应。方法选择笔者所在医院2006年6月~2009年6月收治的中晚期宫颈癌患者,随机分成同步放化疗组(观察组)和单纯放疗组(对照组),并将两组治疗效果及不良反应进行比较。结果观察组CR+PR有效率为93.3%,2年生存率为82.2%;对照组CR+PR有效率为70.0%,2年生存率为55.0%;两组相比差异有统计学意义(P<0.05)。观察组有较明显的骨髓抑制及胃肠道反应,但患者经对症处理后均能耐受。结论同步放化疗治疗中晚期宫颈癌是一种安全、有效、经济的治疗方案,值得临床推广。

关 键 词:中晚期宫颈癌  同步放化疗  不良反应

Curative effect of concomitant chemoradiotherapy for advanced cervical carcinoma
LIU Xiaoqing,DONG Zhuqing. Curative effect of concomitant chemoradiotherapy for advanced cervical carcinoma[J]. China Medicine and Pharmacy, 2011, 0(23): 57-58,60
Authors:LIU Xiaoqing  DONG Zhuqing
Affiliation:Department of Radio Therapy,Mindong Hospital Affiliated Fujian Medical University,Ningde 355000,China
Abstract:Objective To investigate the curative effect and side effect of concomitant chemoradiotherapy to the advanced cervical carcinoma.Methods The patients of advanced cervical carcinoma were randomly divided into two groups From Jun 2006 ~ Jun 2009:concomitant chemoradiotherapy group and only radiotherapy group.The efficacy and adverse effects of both groups were compared.Results In the group of concomitant chemoradiotherapy,the response rate(CR plus PR)were 93.3%,and the 2 year survival rate were 82.2%.In the group of radiotherapy alone,the response rate(CR plus PR)were 70.0%,and the 2 year survival rate were 55.0%.There were significant differences in two groups(P < 0.05).More serious toxicity was found in the group of concomitant chemoradiotherapy,but it could be tolerable.Conclusion Concomitant chemoradiotherapy in advanced cervical carcinoma can acquired curative effect and was safe and economical,so it was worth of clinical application.
Keywords:Advanced cervical carcinoma  Concomitant chemoradiotherapy  Adverse effect
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号